Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Podzamczer

Showing results (81-90 of 181) with videos related to

Pageof 19
Sort By:
BMC Infectious Diseases|April 16, 2022
Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004-2018Lourdes Domínguez-Domínguez, Marta Rava, Otilia Bisbal, et al.
Atherosclerosis|January 31, 2016
Randomized trial of a multidisciplinary lifestyle intervention in HIV-infected patients with moderate-high cardiovascular riskMaria Saumoy, Carlos Alonso-Villaverde, Antonio Navarro, et al.
AIDS (London, England)|September 29, 2012
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravirEsteban Martínez, Polyana M D'Albuquerque, Josep M Llibre, et al.
AIDS (London, England)|March 20, 2010
Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patientsEva Van den Eynde, Juan Manuel Tiraboschi, Cristina Tural, et al.
The Journal of Infectious Diseases|August 1, 2023
Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir AlafenamideSofía Scévola, Jordi Niubó, Pere Domingo, et al.
The Journal of Infectious Diseases|September 1, 2016
HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral RegimenArkaitz Imaz, Javier Martinez-Picado, Jordi Niubó, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|August 24, 2015
Prediction of higher cost of antiretroviral therapy (ART) according to clinical complexity. A validated clinical indexCesar Velasco, Inaki Pérez, Daniel Podzamczer, et al.
Frontiers in Immunology|August 4, 2018
HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy InitiationIsaac Rosado-Sánchez, Inés Herrero-Fernández, Miguel Genebat, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|January 12, 2015
[Barriers to ART initiation in HIV infected subjects and with treatment indication in Spain. Why don't they start their treatment? Bridgap Study]Pompeyo Viciana-Fernández, Vicenç Falcó, Manuel Castaño, et al.
HIV Clinical Trials|December 7, 2017
Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infectionChan-Loi Yong, Joseph C Gathe, Gabriele Knecht, et al.
Pageof 19

Showing results (81-90 of 181) with videos related to

Sort By:
Pageof 19
BMC Infectious Diseases|April 16, 2022
Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004-2018Lourdes Domínguez-Domínguez, Marta Rava, Otilia Bisbal, et al.
Atherosclerosis|January 31, 2016
Randomized trial of a multidisciplinary lifestyle intervention in HIV-infected patients with moderate-high cardiovascular riskMaria Saumoy, Carlos Alonso-Villaverde, Antonio Navarro, et al.
AIDS (London, England)|September 29, 2012
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravirEsteban Martínez, Polyana M D'Albuquerque, Josep M Llibre, et al.
AIDS (London, England)|March 20, 2010
Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patientsEva Van den Eynde, Juan Manuel Tiraboschi, Cristina Tural, et al.
The Journal of Infectious Diseases|August 1, 2023
Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir AlafenamideSofía Scévola, Jordi Niubó, Pere Domingo, et al.
The Journal of Infectious Diseases|September 1, 2016
HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral RegimenArkaitz Imaz, Javier Martinez-Picado, Jordi Niubó, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|August 24, 2015
Prediction of higher cost of antiretroviral therapy (ART) according to clinical complexity. A validated clinical indexCesar Velasco, Inaki Pérez, Daniel Podzamczer, et al.
Frontiers in Immunology|August 4, 2018
HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy InitiationIsaac Rosado-Sánchez, Inés Herrero-Fernández, Miguel Genebat, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|January 12, 2015
[Barriers to ART initiation in HIV infected subjects and with treatment indication in Spain. Why don't they start their treatment? Bridgap Study]Pompeyo Viciana-Fernández, Vicenç Falcó, Manuel Castaño, et al.
HIV Clinical Trials|December 7, 2017
Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infectionChan-Loi Yong, Joseph C Gathe, Gabriele Knecht, et al.
Pageof 19